Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients

Q: What does this research mean for the field?

Achieving both circulating tumor DNA and bone marrow minimal residual disease negativity confers a superior outcome for patients with multiple myeloma. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Sridurga Mithraprabhu; John Reynolds; Hang Quach; Noemi Horvath; Ian Kerridge; Tiffany Khong; Brian G.M. Durie; Andrew Spencer

doi:10.3324/haematol.2023.283831

September 28, 2023HaematologicaOpen Access

Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Circulating tumor DNA and bone marrow minimal residual disease negativity confers

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Mithraprabhu et al. (2023) studied this question.

synapsesocial.com/papers/6a5830e809321dea305fc863 https://doi.org/10.3324/haematol.2023.283831

View Full Paper

Ask AI

Bookmark

Share

Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients

No abstract yet

Ask about this paper

Abstract

Discussion

Cite This Study

Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients

No abstract yet

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading